Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
estradiol .0375 mg/d Patch — NDC 70771-1402-4 (Billing 70771-1402-04)
by Zydus Lifesciences Limited · 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 7 d in 1 PATCH
This is a package of estradiol .0375 mg/d Patch from Zydus Lifesciences Limited, marketed since Nov 2023 and currently FDA-listed. It is this product's only package size.
NDC 70771-1402-04
🏷️ FDA NDC (as labeled)
70771-1402-4
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Estradiol (different manufacturers) — 4 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 12, 2026 — Defective Container; packets were found to be either empty or partially full. (ANI Pharmaceuticals, Inc.) · FDA recall D-0543-2026
Class III · May 16, 2024 — Failed Impurities/Degradation Specifications. (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0543-2024
Class III · May 16, 2024 — Failed Impurities/Degradation Specifications. (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0542-2024
Class III · Feb 21, 2023 — Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point. (Padagis US LLC) · FDA recall D-0464-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
70771-1402-4
Product NDC
70771-1402
11-digit billing NDC
70771140204
UNII
4TI98Z838E
UPC
0370771140343, 0370771140244, 0370771140145, 0370771140442 +2 more
Application #
ANDA202985
SPL Set ID
8b672c79-0896-4d6e-b225-299e89068ad7
Established class (EPC)
Estrogen
Mechanism of action
Estrogen Receptor Agonists
Chemical class
Estradiol Congeners
DEA schedule
Non-controlled
Marketing category
ANDA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2023-11-02
Route
TRANSDERMAL
Dosage form
PATCH
Substance
ESTRADIOL
TE code (Orange Book)
AB2 · RLD · RS
Quick answers
- RxCUI (RxNorm): 238003
Why two NDCs?
The FDA registers this code as 70771-1402-4 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1402-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Radioactive Diagnostic Agent class.
Pharmacologic class
Radioactive Diagnostic Agent, Estrogen
Drug family (ATC)
Natural and semisynthetic estrogens, plain, Progestogens and estrogens, sequential preparations
How it works
Positron Emitting Activity, Estrogen Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
📖 What it is MedlinePlus · NLM
Transdermal estradiol (Climara®, Minivelle®, Vivelle-Dot®) is used to treat hot flashes (hot flushes; sudden feelings of mild or intense body heat) in women who are experiencing menopause (change of life; the end of monthly menstrual periods). Transdermal estradiol (Climara®, Vivelle-Dot®) is also used to treat vaginal dryness, itching, and burning in women who are experiencing menopause. Transdermal estradiol (Climara®, Menostar®, Minivelle®, Vivelle-Dot®) is also used to prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who are experiencing...
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- It's an estrogen used mainly for menopause symptoms like hot flashes and vaginal dryness. Some patches are also used for low estrogen from ovarian problems or to prevent osteoporos...
- That depends on the form. Patches go on the skin once or twice a week depending on the brand, and the injection goes into a muscle. Use the lowest dose that works for the shortest...
- Headache, breast tenderness, spotting or irregular bleeding, cold-like symptoms and skin irritation where a patch sits are the most common. Tell your doctor if they bother you or d...
- Get urgent help for chest pain, sudden weakness or trouble speaking, a swollen painful leg, sudden shortness of breath or sudden vision changes. These could be a stroke or blood cl...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Estradiol — tap one for details:
5
Nutrient depletion considerations
Estradiol may be associated with lower levels of 5 nutrients — worth a chat with your pharmacist, not a cause for alarm.
VITAMIN B6
Insignificant Depletion
VITAMIN C
Insignificant Depletion
ZINC
Insignificant Depletion
FOLIC ACID
Moderate Depletion
MAGNESIUM
Moderate Depletion
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
💬 Questions about estradiol?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $12.90 | $51.61 / 4 patch |
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 3, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 70771-1402-04 You're viewing this Main listing | 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 7 d in 1 PATCH | 2023-11-02 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Estradiol .0375 mg/d 00378-4620-26 | Mylan | 8 patches | $8.262 | AB3 | Availability likely | — |
| Estradiol .0375 mg/d 00378-4643-26 | Mylan | 8 patches | $8.262 | AB1 | Availability likely | — |
| Estradiol .0375 mg/d 70710-1192-08 | Zydus | 8 patches | $8.262 | AB1 | Availability likely | — |
| Lyllana .0375 mg/d 65162-0148-08 | Amneal | 8 pouches | $8.262 | AB3 | Availability likely | — |
| Estradiol .0375 mg/d 68968-3437-08 | Noven | 8 pouches | $8.262 | AB3 | Availability likely | — |
| Dotti .0375 mg/d 65162-0992-08 | Amneal | 8 pouches | $8.262 | AB1 | Availability likely | — |
| Minivelle .0375 mg/d 68968-6637-08 | Noven | 8 pouches | $11.584 | AB3 | Availability likely | — |
| Estradiol .0375 mg/d 00378-3360-99 | Mylan | 4 patches | $11.930 | AB2 | Availability likely | — |
| Estradiol Transdermal System .0375 mg/d 00781-7122-54 | Sandoz | 4 patches | $11.930 | AB2 | Availability likely | — |
| Climara .0375 mg/d 50419-0456-04 | Bayer | 4 patches | $18.298 | AB2 | Availability likely | — |
| Vivelle-Dot .0375 mg/d 66758-0146-83 | Sandoz | 8 patches | $18.376 | AB1 | Availability likely | — |
| Estradiol .0375 mg/d 50090-7987-00 | A-S | 4 pouches | — | AB2 | FDA listed | — |
| estradiol .0375 mg/d 68382-0325-04 | Zydus | 4 patches | — | AB2 | FDA listed | — |
| estradiol .0375 mg/dthis 70771-1402-04 | Zydus | 4 patches | — | AB2 | FDA listed | — |
| Estradiol .0375 mg/d 70771-1564-08 | Zydus | 8 patches | — | AB1 | FDA listed | — |
| Estradiol .0375 mg/d 69238-1630-07 | Amneal | 8 pouches | — | AB1 | FDA listed | — |
| Estradiol .0375 mg/d 50090-7610-00 | A-S | 8 pouches | — | AB3 | FDA listed | — |
| Estradiol .0375 mg/d 00781-7138-40 | Sandoz | 24 patches | — | AB1 | Discontinued | — |
| Estradiol .0375 mg/d 69238-1293-07 | Amneal | 8 pouches | — | AB3 | FDA listed | — |
| Dotti .0375 mg/d 72162-2033-02 | Bryant | 8 pouches | — | AB1 | FDA listed | — |
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2023
On the market since
Nov 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII HR49R9S6XG
A synthetic polymer ingredient used as a film-former and binder in tablet coatings and sustained-release formulations. It helps create a protective layer around the medication to control how and when the drug releases in the body.
-
UNII 25GT92NY0C
A synthetic polymer made from acrylic compounds. It's used in tablet coatings and film formulations to help protect the medicine and control how quickly it dissolves in the body.
-
UNII Z2Z439864Y
Ethyl oleate is a clear liquid derived from oleic acid, a natural fatty acid. In medicines, it acts as a solvent and penetration enhancer, helping dissolve active ingredients and improve their absorption through the skin or mucous membranes.
-
UNII Y98611C087
Glyceryl laurate is an emulsifier made by combining glycerin and lauric acid. It helps mix oil and water-based ingredients together in the medicine and may improve how the product feels or spreads.
-
UNII R8WN29J8VF
Glycidyl methacrylate is a synthetic chemical compound used as a coating or binding agent in pharmaceutical formulations. It helps form protective shells around tablets or capsules and can improve how ingredients stick together in the finished product.
-
UNII 0RE8K4LNJS
Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII L9MK238N77
Vinyl acetate is a synthetic polymer used primarily as a film-coating agent in tablets and capsules. It helps create a smooth, protective outer layer that controls how quickly the medicine dissolves and improves appearance.
9 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA202985 (ANDA)
Labeler code70771
First marketedNov 2023
Product typeHuman Prescription Drug
Portfolio720 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771- 1401 -4 Estradiol Transdermal System, USP 0.025 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA NDC 70771- 1402 -4 Estradiol Transdermal System, USP 0.0375 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA NDC 70771- 1403 -4 Estradiol Transdermal System, USP 0.05 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA NDC 70771- 1404 -4 Estradiol Transdermal System, USP 0.06 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA NDC 70771- 1405 -4 Estradiol Transdermal System, USP 0.075 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA NDC 70771- 1406 -4 Estradiol Transdermal System, USP 0.1 mg/day Continuous Delivery (Once-Weekly) FOR TRANSDERMAL USE ONLY Contains 4 transdermal systems Rx only zydus Pharmaceuticals USA Estradiol Transdermal System USP, 0.025mg per day Estradiol Transdermal System USP, 0.0375mg per day Estradiol Transdermal System USP, 0.05mg per day Estradiol Transdermal System USP, 0.06mg per day Estradiol Transdermal System USP, 0.075mg per day Estradiol Transdermal System USP, 0.1mg per day
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Estradiol — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Estradiol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$65.73M
Claims incl. refills
1.4M
Beneficiaries
1.2M
Spend / beneficiary
$56.27
Spend / claim
$46.97
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
About this NDC listing & data coverage
Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.